eicosapentaenoic acid ethyl ester has been researched along with Hypercholesterolemia in 9 studies
Hypercholesterolemia: A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hypercholesterolemia affects over 34 million adults in the United States and is a major cause of coronary heart disease (CHD)." | 1.39 | New therapeutic alternatives for the management of dyslipidemia. ( Cassagnol, M; Ezzo, D; Patel, PN, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Trivedi, K | 1 |
| Le, V | 1 |
| Nelson, JR | 1 |
| Myran, L | 1 |
| Nguyen, TN | 1 |
| Bhatt, DL | 1 |
| Steg, PG | 1 |
| Miller, M | 1 |
| Brinton, EA | 1 |
| Jacobson, TA | 1 |
| Ketchum, SB | 1 |
| Doyle, RT | 1 |
| Juliano, RA | 1 |
| Jiao, L | 1 |
| Granowitz, C | 1 |
| Tardif, JC | 1 |
| Gregson, J | 1 |
| Pocock, SJ | 1 |
| Ballantyne, CM | 1 |
| Yakubu, A | 1 |
| Azlan, A | 1 |
| Loh, SP | 1 |
| Md Noor, S | 1 |
| Cassagnol, M | 1 |
| Ezzo, D | 1 |
| Patel, PN | 1 |
| Hiatt, WR | 1 |
| Smith, RJ | 1 |
| Piatti, G | 1 |
| Borella, F | 1 |
| Berti, MA | 1 |
| Braga, PC | 1 |
| Nakamura, H | 1 |
| Asano, T | 1 |
| Suzuki, S | 1 |
| Tokonabe, S | 1 |
| Hayakawa, M | 1 |
| Nozaki, S | 1 |
| Matsuzawa, Y | 1 |
| Hirano, K | 1 |
| Sakai, N | 1 |
| Kubo, M | 1 |
| Tarui, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients With Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events With EPA - Intervention Trial)[NCT01492361] | Phase 3 | 8,179 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients with a first occurrence of any component of the composite of CV death or nonfatal MI (including silent MI) during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 392 |
| Placebo | 507 |
The primary outcome measure was the number of patients with a first occurrence of any component of the composite of CV death, nonfatal MI (including silent MI), nonfatal stroke, coronary revascularization, or unstable angina determined to be caused by myocardial ischemia by invasive / non-invasive testing and requiring emergent hospitalization during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 705 |
| Placebo | 901 |
The key secondary outcome measure was the number of patients with a first occurrence of any component of the composite of CV death, nonfatal MI (including silent MI), or nonfatal stroke during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 459 |
| Placebo | 606 |
Number of patients with an occurrence of CV death during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 174 |
| Placebo | 213 |
Number of patients with a first occurrence of fatal or nonfatal MI (including silent MI) during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 250 |
| Placebo | 355 |
Number of patients with a first occurrence of fatal or nonfatal stroke during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 98 |
| Placebo | 134 |
Number of patients with a first occurrence of non-elective coronary revascularization represented as the composite of emergent or urgent classifications during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 216 |
| Placebo | 321 |
Number of patients with a first occurrence of any component of the composite of total mortality, nonfatal MI (including silent MI), or nonfatal stroke during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 549 |
| Placebo | 690 |
Number of patients with an occurrence of death from any cause during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 274 |
| Placebo | 310 |
Number of patients with a first occurrence of unstable angina determined to be caused by myocardial ischemia by invasive / non-invasive testing and requiring emergent hospitalization during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 108 |
| Placebo | 157 |
2 reviews available for eicosapentaenoic acid ethyl ester and Hypercholesterolemia
| Article | Year |
|---|---|
The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Comorbidity; Cost-Benefit Analysis; Cytokines; Ei | 2021 |
Can Yellow Stripe Scad Compete with Salmon on Its Role in Platelet Phospholipid Membrane and Its Cardiovascular Benefits?
Topics: Adult; Animals; Anti-Inflammatory Agents; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, | 2019 |
2 trials available for eicosapentaenoic acid ethyl ester and Hypercholesterolemia
| Article | Year |
|---|---|
Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.
Topics: Aged; Double-Blind Method; Eicosapentaenoic Acid; Female; Follow-Up Studies; Humans; Hydroxymethylgl | 2019 |
Evaluation of ethyl icosapentate in the treatment of hypercholesterolemia in kidney transplant recipients.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Eicosapentaenoic Acid; Fe | 1998 |
5 other studies available for eicosapentaenoic acid ethyl ester and Hypercholesterolemia
| Article | Year |
|---|---|
Icosapent Ethyl (Vascepa) for Hyperlipidemia/Hypercholesterolemia to Reduce Risk of Heart Attack and Stroke.
Topics: Eicosapentaenoic Acid; Humans; Hypercholesterolemia; Lipid Regulating Agents; Myocardial Infarction; | 2021 |
New therapeutic alternatives for the management of dyslipidemia.
Topics: Adult; Anticholesteremic Agents; Benzimidazoles; Coronary Disease; Drug Approval; Eicosapentaenoic A | 2013 |
Assessing the clinical benefits of lipid-disorder drugs.
Topics: Cholesterol; Drug Approval; Eicosapentaenoic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhib | 2014 |
Delaying effects of dietary eicosapentaenoic-docosahexaenoic acids on development of "fatty streaks" in hypercholesterolaemic rabbits. A morphological study by scanning electron microscopy.
Topics: Animals; Cholesterol; Diet; Docosahexaenoic Acids; Eicosapentaenoic Acid; Endothelium, Vascular; Hyp | 1993 |
Effects of purified eicosapentaenoic acid ethyl ester on plasma lipoproteins in primary hypercholesterolemia.
Topics: Adult; Aged; Capsules; Eicosapentaenoic Acid; Fatty Acids; Female; Humans; Hypercholesterolemia; Lip | 1992 |